BCL2 and hematologic disorder: Similarly, MEK1/2 and proteasome inhibitors prevent phosphorylation and following UPS-mediated degradation of Bim, thereby synergistically interacting with Bcl-2 inhibitors in hematologic malignancies (e.g., MM and lymphoma) (43, 96, 97).